Form 8-K - Current report:
SEC Accession No. 0000950170-24-106611
Filing Date
2024-09-16
Accepted
2024-09-16 08:05:09
Documents
12
Period of Report
2024-09-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K krro-20240913.htm   iXBRL 8-K 56651
2 EX-99.1 krro-ex99_1.htm EX-99.1 20241
  Complete submission text file 0000950170-24-106611.txt   241370

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT krro-20240913.xsd EX-101.SCH 54301
15 EXTRACTED XBRL INSTANCE DOCUMENT krro-20240913_htm.xml XML 5062
Mailing Address 60 FIRST STREET 2ND FLOOR, SUITE 250 CAMBRIDGE MA 02141
Business Address 60 FIRST STREET 2ND FLOOR, SUITE 250 CAMBRIDGE MA 02141 617-468-1999
Korro Bio, Inc. (Filer) CIK: 0001703647 (see all company filings)

EIN.: 472324450 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39062 | Film No.: 241299378
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)